Prophylactic treatment for CAR T-cell toxicity shows promising results
Description: For CAR T-cell therapy to become mainstream, the management of related toxicities needs to be addressed. Speaking from the American Society of Hematology (ASH) 2017 Annual Meeting and Exposition in Atlanta, GA, Yi Lin, MD, PhD, of the Mayo Clinic, Rochester, MN, discusses data being presented at the meeting for an additional cohort of the ZUMA-1 study (NCT02348216), investigating the use of tocilizumab for prophylaxis of the primary side effects of axicabtagene ciloleucel (axi-cel; KTE-C19). Dr Lin highlights the results of this treatment in regards to reducing the severity and/or incidence of cytokine release syndrome and neurotoxicity. This video was recorded at the American Society of Hematology (ASH) 2017 Annual Meeting and Exposition in Atlanta, GA.
Shared By : VJHemOnc
Posted on : 01/08/18
Added : 1 year ago